Kyowa Hakko Kirin Licenses Autoimmune Drug From Kirin Amgen JV
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin has signed a licensing agreement and obtained exclusive rights to an autoimmune drug from Amgen Kirin, a California-based joint venture established between Amgen and Kirin Holdings